Triple-negative breast cancer (TNBC) is an aggressive and challenging
subtype of breast cancer characterized by poor prognosis and limited treatment
options. Conventional therapies, primarily based on chemotherapy, often prove
ineffective and are associated with significant side effects. Against this
backdrop, the emergence of immune checkpoint inhibitors (ICI), such as
PD-1/PD-L1 inhibitors, has opened new avenues for treatment. These therapies
stimulate the immune system to recognize and destroy cancer cells and are
generating growing interest. However, their precise role in the management of
TNBC remains to be fully elucidated.
This study evaluates the efficacy and safety of ICIs in treating
unresectable, locally advanced, or metastatic TNBC.
ICIs: A revolution
in TNBC treatment?
To explore this hypothesis, 11 randomized clinical trials involving a
total of 4,314 patients with unresectable, locally advanced, or metastatic TNBC
were selected. The efficacy of the treatment was assessed by analyzing the
following outcomes: overall survival (OS), progression-free survival (PFS),
objective response rate (ORR), and treatment-related adverse events (TRAEs).
Subgroup analyses were also conducted for PD-L1-positive patients to examine
differences in response.
The findings demonstrate that PD-L1 inhibitors significantly improve
OS in both the intention-to-treat and PD-L1-positive populations.
Additionally, PFS also increased in these groups.
While immunotherapies were associated with an increase in
immune-mediated adverse events (such as hypothyroidism, skin rashes, and
pneumonitis), the incidence of severe events was not higher than with
chemotherapy alone.
Finally, combining ICIs with chemotherapy showed superior clinical
benefits compared to monotherapy, further reinforcing their relevance in
managing TNBC.
A new hope in the
fight against tnbc
This study confirms the potential of PD-1/PD-L1 inhibitors to
transform the treatment landscape for advanced TNBC, particularly in
PD-L1-positive patients. While these findings suggest that immunotherapy could
become a cornerstone strategy for managing TNBC, challenges remain. These
include optimizing its use, managing adverse effects, and identifying
predictive biomarkers.
![]()
